

A COLLABORATIVE FORCE FOR CURES

The [Parker Institute for Cancer Immunotherapy](#) is radically changing how research is done. Our model is designed to remove barriers, amplify collaborations and accelerate the development of immune therapies to make all cancers curable. We bring together the top minds in the field. We fuel the boldest ideas. We invest in the talent of today and develop the leaders of tomorrow. And we give our researchers the highest class tools and resources to fuel their work. For us, success doesn't mean we'll never worry about cancer again. [It means we won't have to fear it.](#)

By the Numbers



7 Member
Institutions



40+ Industry &
Nonprofit Collaborations



220+ PICI
Investigators



11 Clinical Trials
in Progress



146 PICI
Supported Projects



14 Scholars, Bridge
Scholars and Fellows

We support [seven renowned institutions](#) and outstanding investigators from [five additional institutions](#) who have made seminal contributions to the field of immuno-oncology. Well over [400](#) people are currently PICI-affiliated, including program and administrative staff at PICI and at our research institutions. Together, we're turning research into real-world treatments.


Research Focuses

PICI takes on high-risk, high-reward research projects in [four promising areas](#) to advance immunotherapy and help patients. We empower our visionary scientists and clinicians to tackle the hardest questions to accelerate the next cancer breakthroughs.

- **CAR-T and Cell Therapy:** To engineer a smarter army of next-gen cell therapies that seek out specific targets and attack cancer—again and again.
- **Checkpoint Inhibitors:** To uncover why some patients respond to checkpoint inhibitors for cancer while others don't. If we know when and how immunotherapy resistance arises, we can prevent or even reverse it.
- **Tumor Antigen Discovery:** To find the “red flags” that show us where cancer is hiding. By pinpointing these antigens that fire up our immune system, we can create more effective personalized anti-cancer therapies.
- **Tumor Microenvironment:** To infiltrate a solid tumor's defenses. How can we break down the tumor microenvironment that walls off cancer from immunotherapy treatments?

The PICI Model

PICI is not just a grantmaker. With robust infrastructure and unique capabilities, we clear the path from idea to outcome. Our cutting-edge tools and resources equip our network to accomplish their most ambitious work.



Research Projects | Tackling immunotherapy's most fundamental questions, working with the best in academia and industry to find answers. Fast.



Clinical Development | Leading multi-site clinical trials with our research institutions. Our in-house trials management and translational medicine experts speed trials from concept to finish line so that discoveries can benefit patients faster.



Strategic Partnerships | Partnerships beyond academia are critical. We work with pharma, biotech companies and nonprofits to propel cancer research. More collaboration means more breakthroughs.



Informatics | PICI statisticians, engineers, data scientists and immunology experts unite to build powerful data platforms to gather and organize data from PICI studies. The end goal: uncover insights and draw conclusions to improve patient responses and develop new treatments.



IP Support | Expert legal guidance at every step, from consulting on a patent application to connecting to negotiating licensing. We help researchers navigate the patent process from discovery to commercialization.



PICI BioTrust | Data studied in isolation limits potential. PICI's BioTrust integrates data to spark ideas and fuel next-level science efficiently and effectively.